



## Synthesis of novel azanorbornylpurine derivatives

Hubert Hřebabecký<sup>a</sup>, Milan Dejmek<sup>a</sup>, Martin Dračinský<sup>a</sup>, Michal Šála<sup>a</sup>, Pieter Leyssen<sup>b</sup>, Johan Neyts<sup>b</sup>, Martina Kaniaková<sup>c</sup>, Jan Krůšek<sup>c</sup>, Radim Nencka<sup>a,\*</sup>

<sup>a</sup> Gilead Sciences & IOCB Research Centre, Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic, v.v.i., Flemingovo nám. 2, 166 10 Prague 6, Czech Republic

<sup>b</sup> Rega Institute for Medical Research, Minderbroedersstraat 10, BE-3000 Leuven, Belgium

<sup>c</sup> Institute of Physiology, Academy of Sciences of the Czech Republic, v.v.i., 142 20 Prague 4, Czech Republic

### ARTICLE INFO

#### Article history:

Received 28 July 2011

Received in revised form 25 October 2011

Accepted 14 November 2011

Available online 25 November 2011

Dedicated to the 75th anniversary of Professor Antonín Holý's birthday

#### Keywords:

Azanorbornane

Purines

Mitsunobu reaction

Coxsackievirus

Hepatitis C virus

Neuronal nicotinic acetylcholine receptor

### ABSTRACT

Azanorbornylpurine derivatives were prepared by Mitsunobu reaction of appropriate hydrox-yazanorbornane derivative with 6-chloropurine or construction of purine base at azanorbornylamines. The prepared target compounds were evaluated for antiviral activity and effect on neuronal and muscle nicotinic acetylcholine receptors.

© 2011 Published by Elsevier Ltd.

## 1. Introduction

Human enteroviruses (HEV) belong to the Enterovirus (EV) genus of the family of the Picornaviridae. They are single stranded, positive sense non-envelop RNA virus with more than 80 serotypes. The genus can be subdivided into HEV-A, HEV-B, HEV-C, HEV-D. Coxsackieviruses B are representative members of the genus.<sup>1</sup> Although mild and self-limiting diseases are the major clinical features of CVB infection, CVB is a common etiological agent of myocarditis and aseptic meningitis.<sup>2,3</sup> Moreover, epidemiological data strongly suggest that enteroviruses, such as Coxsackievirus B4, are associated with type 1 diabetes.<sup>4</sup> Fatalities are often associated with neonatal myocarditis or hepatitis.<sup>5,6</sup> There are no drugs available for the treatment of infections with enteroviruses.<sup>7</sup> Such drugs are urgently needed for the treatment HEV infections.

Recently, we reported on the syntheses of novel potential Coxsackievirus inhibitors based on 6-chloropurines substituted at position 9 with variously modified bicyclic scaffolds.<sup>8</sup> The impact of various substitutions of the purine moiety on the antiviral activity

was also studied.<sup>9</sup> The most active compounds of these series were analogues **1** ( $EC_{50}$   $0.81 \pm 0.20$   $\mu$ M,  $CC_{50} > 50$   $\mu$ M) and **2** ( $0.66 \pm 0.35$   $\mu$ M,  $CC_{50} > 50$   $\mu$ M) (Fig. 1).<sup>8a</sup>




Fig. 1. Structure of compounds **1** and **2**.

This current study concerns the synthesis and antiviral evaluation of novel racemic purine analogues substituted at position 9 with 2-azanorbornane, 7-azanorbornane, and 7-azabenzonorbornane. These compounds exhibit a certain structural analogy to a very potent non-opioid analgesic—epibatidine (**3**, Fig. 2).





Fig. 2. Structure of epibatidine.

\* Corresponding author. Tel.: +420 220 183 265; fax: +420 220 183 560; e-mail address: nencka@uochb.cas.cz (R. Nencka).

Epibatidine was isolated from the skin of the Ecuadorian frog *Epipedobates tricolor*,<sup>10</sup> and shortly afterward it was shown that its analgesic potency is about 200-fold higher than that of morphine. Epibatidine is a highly potent nicotinic acetylcholine receptor agonist.<sup>11</sup> Therefore, evaluation of this biological phenomenon of the target compounds is also subject of the paper.


## 2. Results and discussion

Synthesis of the 2-azanorbornane derivatives started from protected 2-azanorbornene **4**<sup>12</sup> (Scheme 1). Hydroboration of **4** afforded a mixture of hydroxy derivatives **5a** and **5b** in moderate yields (18.5% and 24%, respectively). These alcohols were converted to ketones **6a** and **6b** with pyridinium dichromate in 49% and 92% yield, respectively. The key intermediates, alcohols **7a** and **7b**, were prepared by reduction of ketones **6a** and **6b** with sodium borohydride.



**Scheme 1.** Reagents and conditions: (a) 1.  $\text{BH}_3/\text{THF}$ ,  $\text{THF}$ ,  $0^\circ\text{C}$ , 3 h, 2.  $\text{NaBO}_3$ ,  $\text{H}_2\text{O}/\text{THF}$ , rt, overnight, 18.5% of **5a**, 24% of **5b**; (b) PDC, molecular sieves,  $\text{CH}_2\text{Cl}_2$ , rt, 96 h, 49% of **6a**, 92% of **6b**; (c)  $\text{NaBH}_4$ ,  $\text{CH}_3\text{OH}$ ,  $0^\circ\text{C}$ , 40 min, 85% of **7a**, 98% of **7b**.


The Mitsunobu reaction<sup>13</sup> of **7a** and **7b** with 6-chloro-9H-purine afforded 6-chloropurine derivatives **8a** (72%) and **8b** (38%), respectively (Scheme 2). Ammonolysis of **8a** and **8b** with liquid



**Scheme 2.** Reagents and conditions: (a) 6-chloropurine,  $\text{PPh}_3$ , DIAD,  $\text{THF}$ , rt to reflux, 72% of **8a**, 38% of **8b**; (b) liquid  $\text{NH}_3$ ,  $70^\circ\text{C}$ , 48 h, 91% of **10a**, 93% of **10b**; (c) cyclopropylamine, rt, overnight, 89% of **12a**, 87% of **12b**; (d) TFA,  $\text{CH}_2\text{Cl}_2$ , rt, 3 h, 71% of **9a**, 77% of **9b**, 86% of **13a**, 86% of **13b**; (e) TFA, rt, 3 h, 88% of **11a**, 73% of **11b**.

ammonia at  $75^\circ\text{C}$  gave adenine derivatives **10a** (91%) and **10b** (93%), respectively. Reaction of **8a** and **8b** with cyclopropylamine led to cyclopropylamine derivatives **12a** (89%) and **12b** (87%), respectively. Trifluoroacetic acid salts **9a**, **9b**, **11a**, **11b**, **13a**, and **13b** were obtained by treatment of *tert*-butylcarbonyl derivatives **8a**, **8b**, **10a**, **10b**, **12a**, and **12b**, respectively, with trifluoroacetic acid.

Similarly, we tried to prepare of the 7-aza analogues by Mitsunobu reaction from alcohol **14**<sup>14,15</sup> (Scheme 3). Unfortunately, this reaction led to an inseparable mixture of *exo* and *endo*-isomers **15** and **16**, probably due to the steric effect of the *tert*-butoxycarbonyl group. The mixture was treated with cyclopropylamine giving a mixture of cyclopropylamino derivatives **17** (21%) and **18** (23%), which were easily separated by chromatography on silica gel.



**Scheme 3.** Reagents and conditions: (a) 6-chloropurine,  $\text{PPh}_3$ , DIAD,  $\text{THF}$ , rt to reflux, 52.5% of the mixture **15** and **16**; (b) cyclopropylamine, rt, overnight, 21% of **17**, 23% of **18**; (c) TFA,  $\text{CH}_2\text{Cl}_2$ , rt, 3 h, 74% of **19**, 82% of **20**.

Since the Mitsunobu reaction of alcohol **14** led to a mixture of isomers, it was necessary to find a new route leading unambiguously to the target analogues with the *exo*-oriented purine base. We chose the mercuriazidation<sup>16</sup> of protected 7-azanorbornene **21**<sup>17</sup> for the introduction of the *exo*-amino function. Sodium borohydride reduction of the adduct of 7-azanorbornene **21** and mercuric azide gave amine **23** (85%), which was converted to amine **23** by hydrogenation using  $\text{Pd}(\text{OH})_2$  on activated charcoal as catalyst. The 6-chloropurine base was then constructed by a coupling of the amine **23** with 4,6-dichloropyrimidine-5-amine,<sup>18</sup> and the subsequent ring closure of the obtained pyrimidine derivative **24a** with diethoxymethyl acetate<sup>19</sup> (Scheme 4). This reagent was used in place of the commonly used triethyl orthoformate and mineral acid to avoid deprotection and side reactions. Ammonolysis of chloropurine analogue **15** furnished adenine derivative **25** (86%). Treatment of the *tert*-butylcarbonyl derivatives **15**, **17**, **18**, **24a**, and **25** with trifluoroacetic acid afforded salts of free bases **26**, **19**, **20**, **24b**, and **27**, respectively.

We recently found<sup>8a</sup> that compound **2**, with an annelated benzene ring, exhibits more pronounced antiviral activity than the norbornane analogue **1**, we decided to synthesize 7-azanorbornane analogues with an annelated benzene ring. The synthesis started from the easily accessible benzo derivative **28**<sup>20</sup> as shown in Scheme 5.

Hydroboration of **28** gave hydroxy derivative **29** (78.5%). Treatment of this compound with pyridinium dichromate furnished lactam **30**. This unexpected reaction could be explained by oxidation of the compound **29** in the bridgehead position, which proceeds simultaneously with oxidation of the hydroxy group. Nevertheless, Swern oxidation<sup>21</sup> of **29** gave ketone **31** (90%), which was treated with sodium borohydride affording *endo*-hydroxy derivative **32** (91%). Mitsunobu reaction of **32** with 6-chloropurine led only to *exo*-isomer **33**, but in the very low yield (13%).

Download English Version:

<https://daneshyari.com/en/article/5221057>

Download Persian Version:

<https://daneshyari.com/article/5221057>

[Daneshyari.com](https://daneshyari.com)